Pfizer Announces Corona Virus Vaccine “More Than 90% Preventive Effect” November 9 at 11:31 PM
Pfizer, an American pharmaceutical giant, has released preliminary results for a clinical trial of a new coronavirus vaccine under development, which is “more than 90% prophylodated.”
The vaccine developed by the American pharmaceutical giant Pfizer with the German company Biontec is conducting final clinical trials in the United States and other countries.
Pfizer today released preliminary results of an analysis of clinical trial data by an external independent committee.
Of the 43,538 people involved in clinical trials, 94 were confirmed infected with the new coronavirus.
And, as a result of the analysis comparing the person who actually vaccinated and the person who did not, the effect of the prevention is expected to exceed 90%.
In addition, there was no serious health effect on the inoculated person.
Pfizer says the trial is still in progress and that preventive response figures may change in the future, but will apply to the FDA-U.S. Food and Drug Administration for emergency use after the third week of November with safety data.
As for the prospect of vaccine supply, Pfizer says it will be able to produce 50 million times by the end of the year and up to 1.3 billion times next year, and the Japanese government has agreed on a basic agreement to receive a supply of 60 million by the end of June next year.